Literature DB >> 15252722

Common founder effect of rapsyn N88K studied using intragenic markers.

Vanessa Dunne1, Ricardo A Maselli2,3.   

Abstract

Mutations in the human gene encoding rapsyn have been linked to a recessive form of postsynaptic congenital myasthenic syndrome due to deficient clustering of acetylcholine receptors at the endplate. All patients reported to date carry the N88K mutation, suggesting a possible common founder effect. To decrease the likelihood of a recombination event occurring within the span of neighboring microsatellite markers, we used seven intragenic single nucleotide polymorphisms (SNPs) spanning 8 kb to characterize the haplotype associated with N88K. In three affected N88K homozygous individuals, we identified a common haplotype present in all heterozygous carriers of N88K. Of note, in two asymptomatic N88K homozygous individuals, a second haplotype was present that differed at three SNP sites downstream from the N88K mutation. Our findings of a common haplotype associated with the N88K mutation support a founder effect. The discordant haplotype found in homozygous individuals suggests that recombination events may have occurred within the rapsyn gene and that this may have implications in the phenotypic expression of the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15252722     DOI: 10.1007/s10038-004-0159-y

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  11 in total

1.  Distinct phenotypes of mutant mice lacking agrin, MuSK, or rapsyn.

Authors:  M Gautam; T M DeChiara; D J Glass; G D Yancopoulos; J R Sanes
Journal:  Brain Res Dev Brain Res       Date:  1999-05-14

Review 2.  Sleuthing molecular targets for neurological diseases at the neuromuscular junction.

Authors:  Andrew G Engel; Kinji Ohno; Steven M Sine
Journal:  Nat Rev Neurosci       Date:  2003-05       Impact factor: 34.870

3.  Possible founder effect of rapsyn N88K mutation and identification of novel rapsyn mutations in congenital myasthenic syndromes.

Authors:  P Richard; K Gaudon; F Andreux; E Yasaki; C Prioleau; S Bauché; A Barois; C Ioos; M Mayer; M C Routon; M Mokhtari; J P Leroy; E Fournier; B Hainque; J Koenig; M Fardeau; B Eymard; D Hantaï
Journal:  J Med Genet       Date:  2003-06       Impact factor: 6.318

4.  Rapsyn mutations in hereditary myasthenia: distinct early- and late-onset phenotypes.

Authors:  G Burke; J Cossins; S Maxwell; G Owens; A Vincent; S Robb; M Nicolle; D Hilton-Jones; J Newsom-Davis; J Palace; D Beeson
Journal:  Neurology       Date:  2003-09-23       Impact factor: 9.910

Review 5.  Inference of haplotypes from PCR-amplified samples of diploid populations.

Authors:  A G Clark
Journal:  Mol Biol Evol       Date:  1990-03       Impact factor: 16.240

6.  Rapsyn mutations in humans cause endplate acetylcholine-receptor deficiency and myasthenic syndrome.

Authors:  Kinji Ohno; Andrew G Engel; Xin-Ming Shen; Duygu Selcen; Joan Brengman; C Michel Harper; Akira Tsujino; Margherita Milone
Journal:  Am J Hum Genet       Date:  2002-01-14       Impact factor: 11.025

7.  Identification of pathogenic mutations in the human rapsyn gene.

Authors:  Vanessa Dunne; Ricardo A Maselli
Journal:  J Hum Genet       Date:  2003-03-05       Impact factor: 3.172

8.  Rapsyn mutations in myasthenic syndrome due to impaired receptor clustering.

Authors:  Ricardo A Maselli; Vanessa Dunne; Samuel Ignacio Pascual-Pascual; Constance Bowe; Mark Agius; Rochelle Frank; Robert L Wollmann
Journal:  Muscle Nerve       Date:  2003-09       Impact factor: 3.217

9.  Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice.

Authors:  M Gautam; P G Noakes; J Mudd; M Nichol; G C Chu; J R Sanes; J P Merlie
Journal:  Nature       Date:  1995-09-21       Impact factor: 49.962

10.  E-box mutations in the RAPSN promoter region in eight cases with congenital myasthenic syndrome.

Authors:  Kinji Ohno; Menachem Sadeh; Ilan Blatt; Joan M Brengman; Andrew G Engel
Journal:  Hum Mol Genet       Date:  2003-04-01       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.